In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), with a price target of $11.00. The company’s shares opened today at $1.75.
According to TipRanks, Bodnar is an analyst with an average return of -6.5% and a 36.27% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Context Therapeutics, Dice Therapeutics, and MiNK Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IO Biotech with a $11.33 average price target.
See today’s best-performing stocks on TipRanks >>
IOBT market cap is currently $59.07M and has a P/E ratio of -0.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Read More on IOBT:
